Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy

Journal of Gastroenterology

Volumn 44, Issue SUPPL. 19, 2009, Pages 44-52

  Schlansky, Barry ^a   Hwang, Joo Ha ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Duodenal ulcer; Gastric ulcer; Gastropathy; Nonsteroidal anti inflammatory drugs; Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; CELECOXIB; CLARITHROMYCIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB; SALSALATE; TENOXICAM; UNINDEXED DRUG; VALDECOXIB;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ERADICATION THERAPY; EROSIVE GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PEPTIC ULCER; POLYPHARMACY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STOMACH DISEASE; STOMACH MUCOSA LESION; STOMACH PROTECTION; STOMACH ULCER; TRANSIENT ISCHEMIC ATTACK; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL HEMORRHAGE; HUMANS; PEPTIC ULCER; RISK FACTORS;

EID: 58849155623     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2275-5     Document Type: Review

References (73)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. JAMA 2002;287:337-344.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
3. Wolfe MM, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340(24):1888-1899.
4. Appelboom T. Arthropathy in art and the history of pain management: through the centuries to the cyclooxygenase-2 inhibitors. Rheumatolog y 2002;41(suppl 1):28-34.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
6. Bombardier C, Laine L, Reicin A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 1999;301:669-672.
7. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1861-1890.
8. Simon LS, Weaver AL, Graham DY. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-1928.
9. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison. Lancet 1999;354:2106-2111.
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000;284:1247-1255.
11. Bensen WG, Fiechter JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105.
12. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
13. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
14. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
15. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
16. U.S. Food and Drug Administration Home Page. 7 Apr. 2005.FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 20 Aug. 2007. http://www.fda.gov/bbs/ topics/news/2005/NEW01171.html.
17. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984:1(8390):1311-1315.
18. Chey WD, Scheiman JM. Peptic ulcer disease. In: Friedman LS, McQuaid, Grendell JH, editors. Current diagnosis & treatment in gastroenterology. 2nd ed. New York: McGraw-Hill Medical; 2003. p. 323-354.
19. Arroyo MT, Forne M, de Argila CM, Feu F, Arenas J, de la Vega J, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004;9:249-254.
20. Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Komatsu Y, Kagaya H, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000;12:635-640.
21. Ramsoekh D, van Leerdam ME, Rauws EA, Tytgat GN. Outcome of peptic ulcer bleeding, non-steroidal anti-inflammatory drug use, and Helicobacter pylori infection. Clin Gastroenterol Hepatol 2005;3(9):859-864.
22. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: A systematic review. Clin Gastroenterol Hepatol 2006;4:130-142.
23. Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida T, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006:62(9):765-772.
24. Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130(5):1466-1479.
25. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol Suppl 1999;26:18-24.
26. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413.
27. Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ulcer perforation associated with the use of injectable ketorolac. Ann Pharamacother 1993;27:42-43.
28. Wolfe PA, Polhamus CD, Kubik C, Robinson AB, Clement DJ. Giant duodenal ulcers associated with the postoperative use of ketorolac: Report of three cases. Am J Gastroenterol 1994;89:1110.
29. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
30. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998;93:2037-2046.
31. Simon LS, Hatoum TH, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996;28:204-210.
32. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: Confusion or confounding? Am J Med 2006;119:719-727.
33. Cryer B, Feldman M. Effect of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.
34. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
35. Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: A consensus statement using a meta-analytic approach. Ann Rheum Dis 2004;63:759-766.
36. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006;119:255-266.
37. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002;324:1287-1288.
38. Feldman M. 10 May 2007. COX-2 inhibitors and gastroduodenal toxicity: major clinical trials. UpToDate 21 Aug 2007. http://www.utdol.com.
39. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial. Gastroenterology 2004;127:395-402.
40. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology 2003;42(suppl 3):iIi23-31.
41. Silverstein FE, Graham DY, Senior JR, Davies HY, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:214.
42. Graham DY, Agrawalm NM, Campbell DR, Haber MM, Collis C, Lukasik NL, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 2002;162:169-175.
43. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. BMJ 2004;329:948.
44. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FKL, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-710.
45. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156:2321.
46. Taha AS, Hudson NH, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs. N Engl J Med 1996;334:1435-1439.
47. Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 inhibitors and aspirin. Clin Gastroenterol Hepatol 2006;4:1082-1089.
48. Savage RL, Moller PW, Ballantyne CL, Well JE. Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum 1993;36:84-90.
49. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, et al. Risk of upper gastrointestinal ulcer bleeding with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-1738.
50. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomized trial. Lancet 2007;369:1621-1626.
51. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 2007;297:2018-2024.
52. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-391.
53. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-39.
54. Chan FKL, Ching JYL, Hung LCT, Wong VWS, Leung VKS, Kung NNS, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-244.
55. Vakil N, Connor J. Helicobacter pylori eradication: Equivalence trials and the optimal duration of therapy. Am J Gastroenterol 2005;100:1702-1703.
56. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. Ann Intern Med 2007;146:556-563.
57. Soll AH. 1 Sept. 2005. COX-2 inhibitors and gastroduodenal toxicity: major clinical trials. UpToDate. 21 Aug. 2007. http://www.utdol.com.
58. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: A meta-analysis. Lancet 2002;359:14-22.
59. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-973.
60. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-726.
61. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:727-734.
62. Bianchi Porro G, Lazzaroni M, Manzionna G, Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998;12:355-360.
63. Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-515.
64. U.S. Food and Drug Administration Home Page. 1 Apr 2003. MedWatch. 2002 safety alerts for drugs, biologics, medical devices, and dietary supplements. 21 Aug 2007. http://www.fda.gov/medwatch/safety/2002/ safety02.htm#vioxx.
65. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277.
66. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-1644.
67. Zhang J, Ding E, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials. JAMA 2006;296:1619-1632.
68. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Nonsteroidal anti-inflammatory drugs and myocardial infarctions: Comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007;66:1296-1304.
69. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
70. U.S. Food and Drug Administration Home Page. 8 Sept 2006. MedWatch. Concomitant use of ibuprofen and aspirin. 21 Aug 2007. http://www.fda.gov/CDER/Drug/InfoSheets/HCP/ibuprofen_aspirinHCP.htm.
71. Scheiman JM, Fendrick AM. Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Res Ther 2005;7(suppl 4):S23-S29.
72. Antman EM, Bennett JS, Daughtery A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal Anti-inflammatory drugs: An update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-1642.
73. Fendrick AM. Summing the risk of NSAID therapy. Lancet 2007;369:9573:1580-1581.